Telix to Participate in Oppenheimer and TD Cowen Conferences
Rhea-AI Summary
Telix (ASX: TLX, NASDAQ: TLX) will participate in two investor conferences in late February and early March 2026. Key executives will present and both sessions will be webcast live and available via the company's investor relations website.
Dr. Christian Behrenbruch will join a fireside chat at Oppenheimer on Feb 26, 2026 (4:40 p.m. EST). Kevin Richardson and Dr. Behrenbruch will present at TD Cowen on Mar 2, 2026 (1:50 p.m. EST). Registration and webcast links are on the investor relations events page.
Positive
- None.
Negative
- None.
Market Reaction – TLX
Following this news, TLX has gained 15.20%, reflecting a significant positive market reaction. Our momentum scanner has triggered 13 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $7.73. This price movement has added approximately $346M to the company's valuation. Trading volume is very high at 3.1x the average, suggesting strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
TLX was up 4.68% while key biotech peers showed mixed moves: RARE +6.96%, APLS +3.4%, LGND -1.7%, MLTX -1.46%, ZLAB +0.15%. With no peers in the momentum scanner, the move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings results | Positive | +4.7% | Reported FY 2025 revenue growth and EBITDA with FY 2026 guidance. |
| Feb 17 | Regulatory filing | Positive | -1.8% | Submitted European MAA for TLX101-Px glioma imaging agent. |
| Feb 03 | Earnings webcast notice | Neutral | -0.1% | Announced schedule and access details for FY 2025 results webcast. |
| Jan 20 | Trading update | Positive | -0.4% | Unaudited FY 2025 revenue and Gozellix-driven growth with key milestones. |
| Jan 16 | Clinical trial | Positive | +4.4% | First U.S. patient dosed in BiPASS Phase 3 prostate cancer diagnosis trial. |
Positive fundamental or clinical updates have often seen aligned price gains, while some strong revenue and regulatory milestones have been met with muted or negative reactions.
Over recent months, Telix reported strong FY 2025 growth with US$803.8M revenue and guided to US$950–970M for FY 2026, while investing heavily in R&D and M&A. It advanced its pipeline with a European MAA for TLX101-Px and progress across prostate cancer studies, including first U.S. patient dosing in the BiPASS Phase 3 trial of 250 patients. The current conference-participation news follows this sequence of commercial scaling and regulatory/clinical milestones.
Market Pulse Summary
The stock is surging +15.2% following this news. A strong positive reaction aligns with Telix’s recent backdrop of revenue growth and active pipeline development, as shown by FY 2025 results and new clinical milestones. Participation in high-profile investor conferences can reinforce the story with institutions and broaden coverage. However, past instances show that even solid fundamentals have sometimes met with muted or negative moves, so sustainability has depended on continued execution and clear data or revenue follow-through.
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) and in the TD Cowen 46th Annual Health Care Conference in Boston, MA (U.S.).
Managing Director and Group CEO, Dr. Christian Behrenbruch, will take part in a fireside chat with Oppenheimer on Thursday, February 26, 2026 at 4:40 p.m. EST (Friday, Feb 27 at 8:40 a.m. AEDT).
Kevin Richardson, Chief Executive Officer, Precision Medicine will join Dr. Behrenbruch to present at the TD Cowen conference on Monday, March 2, 2026 at 1:50 p.m. EST (Tuesday, Mar 3 at 5:50 a.m. AEDT).
Both sessions will be webcast live, and accessible through Telix’s Investor Relations website.
For more information including how to register, please visit: https://ir.telixpharma.com/events-presentations.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Telix Investor Relations (U.S.)
Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
FAQ
When will Telix (TLX) present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
Who will represent Telix (TLX) at the TD Cowen 46th Annual Health Care Conference and when?
How can investors watch the Telix (TLX) conference presentations live or on replay?
What time are the Telix (TLX) presentations for international viewers in AEDT?
Where can I find registration details for Telix (TLX) presentations at Oppenheimer and TD Cowen?
